HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 30 Aug 2017
At a glance
- Drugs Entecavir (Primary) ; Peginterferon alfa-2a (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- 21 Aug 2017 Planned End Date changed from 1 Mar 2018 to 1 Jul 2020.
- 21 Aug 2017 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2020.
- 10 Jun 2017 Biomarkers information updated